This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.
Even with the development of advanced technology, the prognosis for CC patients who received radiotherapy is still an intractable problem. Almost 40% suffered disease recurrence among locally advanced patients after radiotherapy and the reported 5-year overall survival is 50-70%. The present FIGO staging is controversial in pre-treatment assessment, which is mainly based on physical examination. An ambiguous diagnosis leads to different treatment strategies and follow-up plans, which is associated with prognosis non-improvement. Incorporation of the tumor involvement features based on the MRI into pre-treatment assessment could standardize and improve the consistency and repeatability of diagnosis.
Study Type
OBSERVATIONAL
Enrollment
200
The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
Fujian Cancer Hospital
Fuzhou, Fujian, China
overall survival
the interval from diagnostic day to death or the last follow-up
Time frame: 1-36 months
progression-free survival
the interval from diagnostic day to death, the last follow-up, or the onset of regional recurrence or distant metastasis
Time frame: 1-36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.